Deloitte's 15th Annual Pharmaceutical Innovation Report analyzes R&D for 20 leading biopharma companies in 2024, showing projected ROI rising to 5.9% from 4.1% in 20231.
GLP-1 therapies for diabetes and obesity are key drivers of the increased returns by addressing unmet medical needs1.
Average drug development cost reached $2.23 billion, with Phase III trial times up 12%, lengthening overall timelines beyond 100 months1.
Thirteen of 20 companies saw IRR growth, with three exceeding 5% increase; report recommends early-stage innovation investment1.
Sources:
1. https://www.prnewswire.com/news-releases/deloittes-15th-annual-pharmaceutical-innovation-report-pharma-rd-returns-continue-upward-for-second-consecutive-year-302410138.html